Several tumor‐specific or associated antigens, including prostate‐specific antigen (PSA), prostate‐specific membrane antigen (PSMA), and prostate acid phosphatase (PAP), have demonstrated significant therapeutic potential in treating PCa. This evidence concerns the gene ACP3 and neoplasm.